Deerfield, Illinois, U.S., October 26, 2026
Vantive announced plans to expand its HomeAdvantage home dialysis offering with Avira, a next-generation automated peritoneal dialysis (APD) cycler designed to support patients receiving kidney treatment at home. The announcement was made during the American Society of Nephrology’s Kidney Week 2026, held in Denver, Colorado, from October 21–25. The planned expansion combines dialysis technology with supplies, technical support, education and digital connectivity to help connect patients, healthcare professionals and support teams throughout treatment. The Avira cycler is designed to provide a guided home dialysis experience with remote patient management and data-sharing capabilities. It is progressing through regulatory review in selected markets and is not yet cleared by the U.S. Food and Drug Administration (FDA) or available for sale in the United States. Vantive also highlighted new evidence on remote patient monitoring, patient education and nursing workforce development, underscoring the importance of coordinated care in expanding access to home-based kidney treatment.
Vantive Plans to Add Avira to HomeAdvantage
The planned addition of Avira automated peritoneal dialysis technology builds on Vantive’s HomeAdvantage offering, which brings together peritoneal dialysis therapy, supply ordering, technical support and educational programmes. The system is powered by the company’s Vantive CONNECT digital solutions, which aim to strengthen communication among patients, care teams and support services. Avira is designed to support a guided home dialysis experience with connectivity that can provide clinicians with remote visibility into treatment information. The company said the device is under review through the FDA’s 510(k) process in the United States and is not yet cleared or available for sale there. Avira has received CE marking under the European Union Medical Device Regulation, indicating that it meets applicable EU regulatory requirements. That marking is separate from U.S. FDA review and does not establish authorization in other countries. The planned expansion forms part of Vantive’s previously announced commitment to invest more than $1 billion in innovation over five years. The company aims to make home dialysis more accessible by combining technology with services and training that help patients manage treatment in their daily lives.
Remote Monitoring Data Highlight Potential Home Dialysis Benefits
Vantive presented new evidence at Kidney Week examining the relationship between remote patient management and outcomes for people receiving peritoneal dialysis. A retrospective observational analysis used administrative claims and data from the Sharesource Connectivity Platform, which connects compatible dialysis cyclers with remote patient management tools. The propensity-score-matched analysis included 2,461 Sharesource users and an equal number of nonusers among U.S. adults receiving peritoneal dialysis between 2020 and 2023. The analysis found that Sharesource use was associated with a lower proportion of patients experiencing hospitalization, at 55.2% compared with 58.9%, and emergency department visits, at 59.5% compared with 65.5%. The median time before transfer to hemodialysis was also longer among platform users, at 39.4 months versus 21.5 months for nonusers. These findings suggest that connected monitoring may help care teams support patients who are receiving dialysis at home. However, the study was observational and cannot prove that the platform caused the differences. The company also clarified that Avira was not evaluated in these studies, so the findings should not be attributed directly to the new cycler.
Advertisement
Education and Nursing Support Remain Essential
Alongside device innovation, Vantive highlighted research into patient education and the home dialysis workforce. A Japanese national survey of 4,187 peritoneal dialysis patients found that primary care physicians were the first source of awareness about peritoneal dialysis for 45.1% of respondents, while nephrologists and patients played important roles in treatment education and therapy selection. The company also highlighted a U.S. survey of 125 home dialysis and hemodialysis nurses examining recruitment and retention challenges. Although 67% of respondents reported receiving zero to three months of training, 54% said they needed more than six months to work independently, and 42% managed more than 15 patients on their own. Respondents identified formal training, mentorship, manageable workloads, compensation, flexible schedules and organizational support as priorities. These findings illustrate that successful home dialysis depends on more than equipment alone: patient awareness, informed treatment choices, trained nursing staff and sustained clinical support are also important. Vantive’s HomeAdvantage expansion reflects an integrated approach that combines technology, education and services to support home-based kidney care.
Source: Vantive press release
